echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > NEJM: Nubeqa (darolutamide) significantly extends the lifespan of patients with non-metastatic prostate cancer!

    NEJM: Nubeqa (darolutamide) significantly extends the lifespan of patients with non-metastatic prostate cancer!

    • Last Update: 2020-09-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The ARAMIS study showed the total lifetime of male patients receiving Nubeqa (darolutamide) combined with ADT for non-metastatic destastic prostate cancer (nmCRPC) compared to placebo combined androgen deprivation therapy (ADT) (OS) has improved significantly (HR s 0.69, 95% CI 0.53-0.88, p s 0.003), and all other secondary endpoints have improved significantly.
    , the rate of adverse events is consistent with the use of ADTs alone.
    results were published recently in the New England Journal of Medicine, NEJM.
    Karim Fizazi, head of research at ARAMIS, said: "Through ongoing research, we have identified treatments that focus on extending life expectancy and reducing side effects in men with nmCRPC."
    men who received drarolutamide combined androgen deprivation therapy (ADT) showed significant improvement in OS compared to placebo combined ADT, and a 31% lower risk of death (HR s 0.69, 95% CI 0.53-0.88, p s 0.003).
    Although more than half (56%) of patients in the placebo group (309 out of 554 patients) received follow-up drarolutamide or other life-extending treatments at the end of the data analysis period (15 November 2019), OS benefits were observed.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.